The 15-minute chart for GSK indicates that the RSI has reached overbought levels, and a Death Cross in the KDJ occurred on May 30, 2025 at 10:45. This suggests that the stock price has risen too quickly and is outpacing its fundamental support, leading to a shift in momentum towards the downside and potentially further declines.
Shares of Spero Therapeutics (SPRO) soared yesterday following the early termination of a phase III study evaluating its investigational oral antibiotic, tebipenem HBr, for complicated urinary tract infections (cUTIs). The study, known as PIVOT-PO, enrolled 1,690 hospitalized adult patients and was stopped early after meeting its primary endpoint of non-inferiority to the standard IV antibiotic imipenem-cilastatin [1].
The positive results from the study have led GSK plc (GSK), Spero's partner, to plan a regulatory filing for FDA approval later this year. The drug, if approved, will be the first oral carbapenem antibiotic for cUTIs, potentially revolutionizing treatment paradigms by reducing hospital stays, lowering costs, and improving patient convenience [1].
SPRO's stock has performed exceptionally well, rising 128% year-to-date compared to a 5% decline in the industry [1]. However, the company's Zacks Rank #4 (Sell) suggests a cautious approach for investors. Other notable biotech stocks with better rankings include Adaptive Biotechnologies (ADPT) and Agenus (AGEN), each with a Zacks Rank #2 (Buy) [1].
Meanwhile, the 15-minute chart for GSK indicates that the Relative Strength Index (RSI) has reached overbought levels, and a Death Cross in the KDJ occurred on May 30, 2025, at 10:45. This technical indicator suggests that the stock price has risen too quickly, potentially leading to a shift in momentum towards the downside and further declines [2].
References:
[1] https://www.nasdaq.com/articles/spro-stock-soars-245-gsk-partnered-uti-drug-meeting-study-goal
[2] https://www.zacks.com/article/gsks-rsi-indicates-potential-bearish-trend
Comments
No comments yet